ResearcherHomi Bhabha National InstituteActive in the last 2 years
Vikas S. Ostwal
Matched on ORCID iD 0000-0002-0067-4748; OpenAlex author ID A5026760266, A5056573159. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 23
2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper
Papers 8
- Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.06.004↗
- Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampull… Last author DOI 10.1007/s12029-023-00936-1↗
- Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis. Last author DOI 10.4103/ijmr.ijmr_980_21↗
- Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Co-author DOI 10.1016/j.surg.2021.10.018↗
- Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
- Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients? Co-author DOI 10.4103/ijc.ijc_552_17↗
- Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Co-author DOI 10.4103/ijmr.ijmr_249_17↗
- Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. Co-author DOI 10.4103/ijc.ijc_377_17↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anant Ramaswamy · 7 shared papers, 2017–2024 · strength 0.90
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of … DOI 10.4103/ijmr.ijmr_980_21↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Shailesh Vinayak Shrikhande · 7 shared papers, 2017–2024 · strength 0.79
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Vikram Anil Chaudhari · 3 shared papers, 2022–2024 · strength 0.47
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Manish Suresh BHANDARE · 3 shared papers, 2022–2024 · strength 0.47
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Abhishek Mitra · 2 shared papers, 2019–2022 · strength 0.21
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and H… DOI 10.1097/sla.0000000000002633↗
- Bhawna Sirohi · 1 shared paper, 2022 · strength 0.14
- Shivendra Singh · 1 shared paper, 2023 · strength 0.12
- Vaibhav Kumar Varshney · 1 shared paper, 2023 · strength 0.12
- Adarsh Chaudhary · 1 shared paper, 2023 · strength 0.12
- Zhi Ven Fong · 1 shared paper, 2019 · strength 0.07
- Arja Gerritsen · 1 shared paper, 2019 · strength 0.07
- Carlos Fernández-del Castillo · 1 shared paper, 2019 · strength 0.07
- L. Bengt van Rijssen · 1 shared paper, 2019 · strength 0.07
- Jin Peng He · 1 shared paper, 2019 · strength 0.07
- Johanna W. Wilmink · 1 shared paper, 2019 · strength 0.07
- Laura Maggino · 1 shared paper, 2019 · strength 0.07
- Hanneke W.M. van Laarhoven · 1 shared paper, 2019 · strength 0.07
- Christopher Lee Wolfgang · 1 shared paper, 2019 · strength 0.07
- Jin‐Young Jang · 1 shared paper, 2019 · strength 0.07
- Marc G. Besselink · 1 shared paper, 2019 · strength 0.07
- Claudio Bassi · 1 shared paper, 2019 · strength 0.07
- Sun‐Whe Kim · 1 shared paper, 2019 · strength 0.07
- Ammar A. Javed · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.